Wednesday, July 8, 2026

Drug profile · INN

mitapivat sulfate

mitapivat sulfate (PYRUKYND) is a pyruvate kinase isozymes r/l activator. Associated with Agios Netherlands B.V.. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 20
Pipeline programs 7
News articles 0
Drug details — mitapivat sulfate
US status
approved
Class
Route
ORAL
Patents
20
Programs
7
Data quality
0.89

Quick answer

mitapivat sulfate (PYRUKYND) is a pyruvate kinase isozymes r/l activator. Associated with Agios Netherlands B.V.. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN mitapivat sulfate
Brand PYRUKYND
Mechanism Pyruvate kinase isozymes R/L activator
Target Pyruvate kinase PKLR
Route ORAL
Formulation TABLET

Mechanism of action

Pyruvate kinase isozymes R/L activator

Primary target: Pyruvate kinase PKLR

Approval history

Authority Status Date
FDA approved

Pipeline programs

  1. Mitapivat Phase 3 · Agios Netherlands · Non-Transfusion-dependent Alpha-Thalassemia
  2. Mitapivat Phase 3 · Agios Netherlands · Pediatric Pyruvate Kinase Deficiency
  3. Mitapivat Phase 3 · Agios Netherlands · Sickle Cell Disease
  4. Mitapivat Phase 2 · Agios Netherlands · Anemia
  5. Mitapivat Phase 1 · Agios Netherlands · Moderate Hepatic Impairment
  6. Mitapivat Phase 1 · Agios Netherlands · Healthy Participants
  7. Mitapivat Approved · Agios Netherlands · Pyruvate Kinase Deficiency

Related & competitor drugs

  1. mitapivat Blood and blood forming organs (B06)
  1. US 12428376

    Therapeutic compounds and compositions

    Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 12133853

    Pyruvate kinase activators for use in treating blood disorders

    Expires Mon Oct 31 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. US 11957680

    Pyruvate kinase activators for use in treating blood disorders

    Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  4. US 11919915

    Compounds and methods useful for stabilizing phenylalanine hydroxylase mutations

    Expires Mon Feb 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  5. US 11878049

    Mitapivat therapy and modulators of cytochrome P450

    Expires Mon Jan 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  6. US 11872225

    Pyruvate kinase modulators and use thereof

    Expires Mon Jan 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  7. US 11866411

    Therapeutic compounds and compositions

    Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  8. US 11793806

    Pyruvate kinase activators for use in therapy

    Expires Mon Oct 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  9. US 11590132

    Pyruvate kinase activators for use in treating blood disorders

    Expires Mon Feb 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  10. US 11464775

    Pyruvate kinase modulators and use thereof

    Expires Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  11. US 11364240

    Pyruvate kinase activators for use in treating blood disorders

    Expires Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  12. US 11254652

    Crystalline forms of N-(4-(4-(cyclopropymethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide

    Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  13. US 11234976

    Methods of using pyruvate kinase activators

    Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  14. US 11040036

    Pyruvate kinase activators for use in treating blood disorders

    Expires Mon Jun 17 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  15. US 11021515

    Therapeutically active compounds and their methods of use

    Expires Mon May 27 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  16. US 10988448

    Therapeutic compounds and compositions

    Expires Mon Apr 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  17. US 10946023

    Therapeutically active compounds and their methods of use

    Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  18. US 10730854

    Therapeutically active compounds and their methods of use

    Expires Mon Jul 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  19. US 10689375

    Compounds and their methods of use

    Expires Mon Jun 18 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  20. US 10689414

    Therapeutically active compounds and their methods of use

    Expires Mon Jun 18 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is mitapivat sulfate?

mitapivat sulfate (PYRUKYND) is a pyruvate kinase isozymes r/l activator. Associated with Agios Netherlands B.V.. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for mitapivat sulfate?

PYRUKYND is a marketed brand name for mitapivat sulfate. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of mitapivat sulfate?

mitapivat sulfate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.